Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...